The limitation of this study is the nonmeasurement of the inflammatory factors and immunostaining for macrophage markers (F4/80 or Iba-1). Further investigations on differentiation of hUCBSCs along with the use of MO extracts will provide further evidence regarding the therapeutic effectiveness of hUCBSCs after SCI.